Trade name | â‘ Empagliflozin â‘¡Canagliflozin â‘¢Dapagliflozin â‘£Ertugliflozin |
---|---|
Target organ | Proximal tubule of kidney |
Favorable aspects | â‘ Lower blood glucose |
â‘¡Lower blood pressure (reduce systolic BP by 2.46 mmHg and diastolic BP by 1.46 mmHg) | |
③Lower body weight (3 kg–4 kg reduction) | |
④Lower glycosylated hemoglobin (0.7%–1% reduction) | |
⑤Increase high-density lipoprotein (HDL) cholesterol, and decrease triglycerides. | |
â‘¥Reduce albuminuria | |
⑦Reduce uric acid (10%–15% reduction) | |
⑧Increase hematocrit (2–4% increase) | |
Unfavorable aspects | â‘ Urinary tract infection |
â‘¡Genital fungal infection | |
â‘¢Ketoacidosis | |
â‘£Fracture | |
⑤Malignant tumor | |
â‘¥Hypotension | |
⑦Dehydration | |
⑧Hypoglycemia | |
⑨Lower limb amputation |